Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction

Serge Elsasser, Elio Donna, Cuneyt M. Demirozu, Ignacio Danta, Adam Wanner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We investigated whether the bronchodilator response to a β-adrenergic agonist is influenced by the mechanism of induced bronchoconstriction. Normal subjects and asymptomatic asthmatics inhaled a dry, aerosol (mass median aerodynamic diameter, 1.5 μm) with increasing concentrations of methacholine or histamine to produce a 35% decrease in specific airway conductance (SGaw), followed by a single inhalation of a metaproterenol aerosol. By studying normal subjects and asthmatics, we were able to compare metaproterenol responsiveness after widely divergent doses of the bronchoprovocative agents but the same degree of bronchoconstriction. Airway deposition of methacholine, histamine, and metaproterenol was measured using a quinine fluorescence technique. Mean baseline SGaw, metaproterenol responsiveness, and metaproterenol mass deposited were similar in normal subjects and asthmatics. Likewise, mean SGaw after completion of methacholine and histamine challenge, and the subsequently deposited metaproterenol mass were similar in the two groups. After methacholine challenge (mean ± SD provocative drug mass causing a 35% decrease in SGaw, PM35: 8.94±5.96 μmol in normal subjects and 0.30±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 89±33% in normal subjects and by 190±55% in asthmatics (p<0.05, two-way analysis of variance). After histamine challenge (PM35, 2.92±2.49 μmol in normal subjects and 0.17±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 111±38% in normal subjects and 113±69% in asthmatics (p = not significant). Thus, for the same degree of bronchoconstriction, metaproterenol responsiveness was influenced by the dose of methacholine but not the dose of histamine. The differential metaproterenol response could be related to a functional antagonism between muscarinic and β-adrenergic agonists.

Original languageEnglish
Pages (from-to)617-623
Number of pages7
JournalChest
Volume110
Issue number3
StatePublished - Dec 1 1996

Fingerprint

Metaproterenol
Bronchoconstriction
Methacholine Chloride
Histamine
Adrenergic Agonists
Aerosols
Muscarinic Agonists
Quinine
Bronchodilator Agents
Inhalation
Analysis of Variance
Fluorescence

Keywords

  • airway hyperresponsiveness
  • functional antagonism
  • histamine
  • methacholine
  • sympathomimetic agents

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction. / Elsasser, Serge; Donna, Elio; Demirozu, Cuneyt M.; Danta, Ignacio; Wanner, Adam.

In: Chest, Vol. 110, No. 3, 01.12.1996, p. 617-623.

Research output: Contribution to journalArticle

Elsasser, Serge ; Donna, Elio ; Demirozu, Cuneyt M. ; Danta, Ignacio ; Wanner, Adam. / Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction. In: Chest. 1996 ; Vol. 110, No. 3. pp. 617-623.
@article{464af1014a18417a9b4396b2d41881b5,
title = "Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction",
abstract = "We investigated whether the bronchodilator response to a β-adrenergic agonist is influenced by the mechanism of induced bronchoconstriction. Normal subjects and asymptomatic asthmatics inhaled a dry, aerosol (mass median aerodynamic diameter, 1.5 μm) with increasing concentrations of methacholine or histamine to produce a 35{\%} decrease in specific airway conductance (SGaw), followed by a single inhalation of a metaproterenol aerosol. By studying normal subjects and asthmatics, we were able to compare metaproterenol responsiveness after widely divergent doses of the bronchoprovocative agents but the same degree of bronchoconstriction. Airway deposition of methacholine, histamine, and metaproterenol was measured using a quinine fluorescence technique. Mean baseline SGaw, metaproterenol responsiveness, and metaproterenol mass deposited were similar in normal subjects and asthmatics. Likewise, mean SGaw after completion of methacholine and histamine challenge, and the subsequently deposited metaproterenol mass were similar in the two groups. After methacholine challenge (mean ± SD provocative drug mass causing a 35{\%} decrease in SGaw, PM35: 8.94±5.96 μmol in normal subjects and 0.30±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 89±33{\%} in normal subjects and by 190±55{\%} in asthmatics (p<0.05, two-way analysis of variance). After histamine challenge (PM35, 2.92±2.49 μmol in normal subjects and 0.17±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 111±38{\%} in normal subjects and 113±69{\%} in asthmatics (p = not significant). Thus, for the same degree of bronchoconstriction, metaproterenol responsiveness was influenced by the dose of methacholine but not the dose of histamine. The differential metaproterenol response could be related to a functional antagonism between muscarinic and β-adrenergic agonists.",
keywords = "airway hyperresponsiveness, functional antagonism, histamine, methacholine, sympathomimetic agents",
author = "Serge Elsasser and Elio Donna and Demirozu, {Cuneyt M.} and Ignacio Danta and Adam Wanner",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "110",
pages = "617--623",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction

AU - Elsasser, Serge

AU - Donna, Elio

AU - Demirozu, Cuneyt M.

AU - Danta, Ignacio

AU - Wanner, Adam

PY - 1996/12/1

Y1 - 1996/12/1

N2 - We investigated whether the bronchodilator response to a β-adrenergic agonist is influenced by the mechanism of induced bronchoconstriction. Normal subjects and asymptomatic asthmatics inhaled a dry, aerosol (mass median aerodynamic diameter, 1.5 μm) with increasing concentrations of methacholine or histamine to produce a 35% decrease in specific airway conductance (SGaw), followed by a single inhalation of a metaproterenol aerosol. By studying normal subjects and asthmatics, we were able to compare metaproterenol responsiveness after widely divergent doses of the bronchoprovocative agents but the same degree of bronchoconstriction. Airway deposition of methacholine, histamine, and metaproterenol was measured using a quinine fluorescence technique. Mean baseline SGaw, metaproterenol responsiveness, and metaproterenol mass deposited were similar in normal subjects and asthmatics. Likewise, mean SGaw after completion of methacholine and histamine challenge, and the subsequently deposited metaproterenol mass were similar in the two groups. After methacholine challenge (mean ± SD provocative drug mass causing a 35% decrease in SGaw, PM35: 8.94±5.96 μmol in normal subjects and 0.30±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 89±33% in normal subjects and by 190±55% in asthmatics (p<0.05, two-way analysis of variance). After histamine challenge (PM35, 2.92±2.49 μmol in normal subjects and 0.17±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 111±38% in normal subjects and 113±69% in asthmatics (p = not significant). Thus, for the same degree of bronchoconstriction, metaproterenol responsiveness was influenced by the dose of methacholine but not the dose of histamine. The differential metaproterenol response could be related to a functional antagonism between muscarinic and β-adrenergic agonists.

AB - We investigated whether the bronchodilator response to a β-adrenergic agonist is influenced by the mechanism of induced bronchoconstriction. Normal subjects and asymptomatic asthmatics inhaled a dry, aerosol (mass median aerodynamic diameter, 1.5 μm) with increasing concentrations of methacholine or histamine to produce a 35% decrease in specific airway conductance (SGaw), followed by a single inhalation of a metaproterenol aerosol. By studying normal subjects and asthmatics, we were able to compare metaproterenol responsiveness after widely divergent doses of the bronchoprovocative agents but the same degree of bronchoconstriction. Airway deposition of methacholine, histamine, and metaproterenol was measured using a quinine fluorescence technique. Mean baseline SGaw, metaproterenol responsiveness, and metaproterenol mass deposited were similar in normal subjects and asthmatics. Likewise, mean SGaw after completion of methacholine and histamine challenge, and the subsequently deposited metaproterenol mass were similar in the two groups. After methacholine challenge (mean ± SD provocative drug mass causing a 35% decrease in SGaw, PM35: 8.94±5.96 μmol in normal subjects and 0.30±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 89±33% in normal subjects and by 190±55% in asthmatics (p<0.05, two-way analysis of variance). After histamine challenge (PM35, 2.92±2.49 μmol in normal subjects and 0.17±0.29 μmol in asthmatics), metaproterenol increased mean SGaw by 111±38% in normal subjects and 113±69% in asthmatics (p = not significant). Thus, for the same degree of bronchoconstriction, metaproterenol responsiveness was influenced by the dose of methacholine but not the dose of histamine. The differential metaproterenol response could be related to a functional antagonism between muscarinic and β-adrenergic agonists.

KW - airway hyperresponsiveness

KW - functional antagonism

KW - histamine

KW - methacholine

KW - sympathomimetic agents

UR - http://www.scopus.com/inward/record.url?scp=0030462273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030462273&partnerID=8YFLogxK

M3 - Article

VL - 110

SP - 617

EP - 623

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -